A�’��}�c�ˆ���5�g7r,�)Pֱ��OE��9+ɯX�4y�(��uȰprf+]/E�@�$ʣ���+*�e��z��$��!Xז�lv��_�|ē�����。

Mace, activist dispute handshake that resulted in arrestNone

Newsmakers for November 24

MG Cyberster India-Spec Unveiled: 510 PS Power and 77 kWh Slim Battery Pack

Climate change: Nigerian researcher leverages AI for biodiversity conservation

12 analysts have shared their evaluations of Waters WAT during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 8 2 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 5 1 0 3M Ago 1 0 1 1 0 Analysts have recently evaluated Waters and provided 12-month price targets. The average target is $380.83, accompanied by a high estimate of $430.00 and a low estimate of $325.00. This current average reflects an increase of 10.53% from the previous average price target of $344.55. Exploring Analyst Ratings: An In-Depth Overview The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Sung Ji Nam Scotiabank Announces Sector Perform $430.00 - Derik De Bruin B of A Securities Raises Neutral $430.00 $400.00 Justin Bowers Deutsche Bank Raises Hold $325.00 $310.00 Eve Burstein Bernstein Raises Market Perform $360.00 $345.00 Dan Brennan TD Cowen Raises Hold $410.00 $363.00 Daniel Arias Stifel Raises Hold $360.00 $332.00 Rachel Vatnsdal JP Morgan Raises Neutral $380.00 $340.00 Brandon Couillard Wells Fargo Raises Overweight $415.00 $380.00 Luke Sergott Barclays Raises Underweight $360.00 $330.00 Luke Sergott Barclays Raises Underweight $330.00 $300.00 Tycho Peterson Jefferies Raises Buy $415.00 $355.00 Vijay Kumar Evercore ISI Group Raises In-Line $355.00 $335.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company. Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market. Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Waters's stock. This examination reveals shifts in analysts' expectations over time. Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waters's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table. Stay up to date on Waters analyst ratings. All You Need to Know About Waters Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. Financial Insights: Waters Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges. Revenue Growth: Over the 3 months period, Waters showcased positive performance, achieving a revenue growth rate of 4.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector. Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.82%, the company showcases strong profitability and effective cost control. Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.71% ROE, the company effectively utilizes shareholder equity capital. Return on Assets (ROA): Waters's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.6% ROA, the company effectively utilizes its assets for optimal returns. Debt Management: With a high debt-to-equity ratio of 1.19 , Waters faces challenges in effectively managing its debt levels, indicating potential financial strain. The Significance of Analyst Ratings Explained Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter. Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts. Breaking: Wall Street's Next Big Mover Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details . This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.The travel agency eyeing Syria: 'Many parts of the country have been safe to visit for years'

AP News Summary at 6:13 p.m. EST

Dave Hyde: Josh Allen Jr.? Once kings, 3-8 Patriots present an unbridled player Dolphins must controlBuilding trades union gives Service to Labor Awards, donates toys to needy kids

NoneMidcoast Youth Center appoints new senior program director

None

NEW YORK--(BUSINESS WIRE)--Nov 24, 2024-- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”). Metagenomi describes itself as a “genetics medicine company.” For more information, submit a form , email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Metagenomi, Inc. (NASDAQ: MGX) Misled Investors Regarding its Business Operations. According to the lawsuit, Metagenomi introduced itself to investors during its IPO as a “genetic medicines company” having a long-standing business relationship with Moderna, one of the leading Covid-19 vaccine companies. Integral to Metagenomi’s collaboration with Moderna was the claim that the two companies had entered into a Strategic Collaboration and License Agreement on October 29, 2021, which included multiple four-year research programs and a subsequent licensed product-by-licensed product agreement. Metagenomi completed its initial public offering on February 13, 2024, selling 6.25 million shares at $15 per share. However, less than three months later, on May 1, 2024, Metagenomi announced that it and Moderna had “mutually agreed to terminate their collaboration” agreement. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Metagenomi, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by November 25, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. View source version on businesswire.com : https://www.businesswire.com/news/home/20241124410010/en/ CONTACT: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Rosen Law Firm, P.A. Copyright Business Wire 2024. PUB: 11/24/2024 09:37 AM/DISC: 11/24/2024 09:35 AM http://www.businesswire.com/news/home/20241124410010/en

Tennessee 32, Houston 27GSA Capital Partners LLP bought a new stake in shares of Empire State Realty Trust, Inc. ( NYSE:ESRT – Free Report ) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 23,066 shares of the real estate investment trust’s stock, valued at approximately $256,000. Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Signaturefd LLC raised its holdings in Empire State Realty Trust by 81.6% during the third quarter. Signaturefd LLC now owns 3,391 shares of the real estate investment trust’s stock valued at $38,000 after acquiring an additional 1,524 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Empire State Realty Trust by 35.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,412 shares of the real estate investment trust’s stock valued at $59,000 after acquiring an additional 1,419 shares during the period. Ballentine Partners LLC bought a new stake in Empire State Realty Trust during the third quarter valued at about $129,000. Mercer Global Advisors Inc. ADV bought a new stake in Empire State Realty Trust during the second quarter valued at about $137,000. Finally, Creative Planning raised its holdings in Empire State Realty Trust by 20.5% during the third quarter. Creative Planning now owns 12,598 shares of the real estate investment trust’s stock valued at $140,000 after acquiring an additional 2,145 shares during the period. 67.10% of the stock is currently owned by hedge funds and other institutional investors. Empire State Realty Trust Stock Performance Shares of ESRT stock opened at $11.08 on Friday. The business’s fifty day simple moving average is $10.93 and its 200-day simple moving average is $10.25. The company has a market cap of $1.85 billion, a PE ratio of 41.04 and a beta of 1.40. The company has a current ratio of 3.72, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. Empire State Realty Trust, Inc. has a 12-month low of $8.39 and a 12-month high of $11.62. Wall Street Analyst Weigh In Several equities research analysts have recently issued reports on ESRT shares. StockNews.com cut Empire State Realty Trust from a “hold” rating to a “sell” rating in a report on Saturday, November 2nd. BMO Capital Markets lifted their target price on Empire State Realty Trust from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. Finally, Wells Fargo & Company lifted their target price on Empire State Realty Trust from $7.00 to $10.00 and gave the stock an “underweight” rating in a report on Wednesday, September 11th. Check Out Our Latest Analysis on ESRT About Empire State Realty Trust ( Free Report ) Empire State Realty Trust, Inc (NYSE: ESRT) is a NYC-focused REIT that owns and operates a portfolio of modernized, amenitized, and well-located office, retail, and multifamily assets. The company is the recognized leader in energy efficiency and indoor environmental quality. ESRT’s flagship Empire State Building – the “World’s Most Famous Building” – includes its Observatory, Tripadvisor’s 2023 Travelers’ Choice Awards: Best of the Best the #1 attraction in the US for two consecutive years. Read More Five stocks we like better than Empire State Realty Trust The 3 Best Retail Stocks to Shop for in August Vertiv’s Cool Tech Makes Its Stock Red-Hot With Risk Tolerance, One Size Does Not Fit All MarketBeat Week in Review – 11/18 – 11/22 The How and Why of Investing in Gold Stocks 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Empire State Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Empire State Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter .